Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest treatment options for this condition.

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

1 The prospective, multicenter study is published in the Journal of Psoriasis and Psoriatic Arthritis. “Female sex was associated with shorter overall drug survival for all biologics combined ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

A shared neuroimmune pathway involving CRH, mast cells, and Th17 cells may underlie the link between psoriatic arthritis and ...

highlighting the antibody-based drug’s efficacy as a first-line option for patients with active psoriatic arthritis ((PsA)). JNJ said that Tremfya, which is already approved in the U.S. for PsA ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic arthritis (PsA). The APEX trial has been comparing the drug against placebo ...

Factors associated with multi-b/tsDMARD failure among patients with PsA included female sex, obesity, depression, axial disease, and increased disease activity.

(RTTNews) - Drug major Johnson & Johnson (JNJ) announced Friday positive results from the TREMFYA (guselkumab) Phase 3b APEX study in adults living with active psoriatic arthritis or PsA ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a Canadian cohort study showed.